Predictors of drug survival of biologic therapies in psoriasis patients

References

• Van de Kerkhof PCM, O Nestle F. Psoriasis. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 3rd ed. London: Elsevier; 2012. p. 135–157.
   Google Scholar
• Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854–862.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke W-H, Mrowietz U, et al. S3 – guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10:1–95.
   Web of Science ®Google Scholar
• Alper S, Atakan N, Ali Gürer M, et al. Turkish guideline for the treatment of psoriasis-2016. Turkderm - Turkderm. 2010;44(2):105–112.
   Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–273.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Karczewski J, Poniedziałek B, Rzymski P, et al. Factors affecting response to biologic treatment in psoriasis. Dermatol Ther. 2014;27(6):323–330.
   PubMed Web of Science ®Google Scholar
• Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis evidence from the Psocare project. Dermatology. 2008;217(4):365–373.
   PubMed Web of Science ®Google Scholar
• Carretero G, Ferrandiz C, Dauden E, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2015;29(1):156–1950.
   PubMed Web of Science ®Google Scholar
• Antoniou C, Dessinioti C, Stratigos A, et al. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution’s experience. J Eur Acad Dermatol Venereol. 2009;23(8):979–982.
   PubMed Web of Science ®Google Scholar
• Marinas JEC, Kim WB, Shahbaz A, et al. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: a Canadian multicentre retrospective study. Australas J Dermatol. 2018;59(1):e11–14.
   PubMed Web of Science ®Google Scholar
• Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–1065.
   PubMed Web of Science ®Google Scholar
• Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: report from the psoriasis registry Austria. Acta Derm Venerol. 2016;96(2):207–212.
   PubMed Web of Science ®Google Scholar
• No DJ, Inkeles MS, Amin M, et al. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29(5):460–466.
   PubMed Web of Science ®Google Scholar
• Iskandar IYK, Warren RB, Lunt M, et al. Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138(4):775–784.
   PubMed Web of Science ®Google Scholar
• Reek JMPA, Zweegers J, Kievit W, et al. Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014;171(5):1189–1196.
   PubMed Web of Science ®Google Scholar
• Oostveen A, Bergboer J, Kerkhof P, et al. Genotype–phenotype correlations in a prospective cohort study of paediatric plaque psoriasis: lack of correlation between HLA-C*06 and family history of psoriasis. Acta Derm Venerol. 2014;94(6):667–671.
   PubMed Web of Science ®Google Scholar
• Cibulova A, Zajacova M, Fojtikova M, et al. The HLA-Cw*06 allele and – 21149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population. Rheumatol Int. 2013;33(4):913–919.
   PubMed Web of Science ®Google Scholar
• Bergboer JGM, Oostveen AM, De Jager MEA, et al. Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C-LCE3B deletion and HLA-C*06. Br J Dermatol. 2012;167(4):922–925.
   PubMed Web of Science ®Google Scholar
• Ryan C, Kelleher J, Fagan MF, et al. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis. Clin Exp Dermatol. 2014;39(4):519–524.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Sgambato A, Fanali C, et al. HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients. Pharmacogenet Genomics. 2016;26(9):423–427.
   PubMed Web of Science ®Google Scholar
• van den Reek J, Coenen MJH, van de L’Isle Arias M, et al. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis. Br J Dermatol. 2017;176(5):1288–1296.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Wang TS, Chan CC, et al. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014;171(5):1181–1188.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, van den Reek JM, et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017;177(2):489–496.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chimenti S, et al. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol. 2016;74(2):374–375.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Boca AN, Botti E, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology. 2016;232(2):230–236.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127–132.
   PubMedGoogle Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69(5):817–821.
   PubMed Web of Science ®Google Scholar